Animal Models for Autoimmune Hepatitis: Are Current Models Good Enough?

Area of Science:

• Immunology
• Hepatology
• Translational Medicine

Background:

• Autoimmune liver diseases (AILDs) encompass autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and IgG4-related cholangitis (IAC).
• Current AIH therapy relies on glucocorticoids and cytostatic drugs, while cholestatic AILDs use bile acids; however, many patients lack adequate response or suffer side effects.
• Existing treatments are often symptomatic or carry significant adverse effects, highlighting the need for improved therapeutic strategies.

Purpose of the Study:

• To review the current status of animal models for autoimmune hepatitis (AIH).
• To explore discrepancies between findings in animal models and human patient realities.
• To identify potential strategies for overcoming these translational gaps.

Main Methods:

• Review of existing literature on AIH pathogenesis and animal models.
• Analysis of factors contributing to the translational gap between animal models and human patients.
• Discussion of potential solutions, including the use of humanized animal models.

Main Results:

• Animal models have been instrumental in elucidating AIH pathogenesis and identifying therapeutic targets.
• Significant differences exist between animal models and human patients, including genetic background, housing, nutrition, and microbiome.
• These discrepancies limit the reliable translation of findings from animal models to clinical practice.

Conclusions:

• Despite decades of research using animal models, precise and universally effective treatments for AIH remain elusive.
• Humanized animal models and consideration of environmental factors may help bridge the gap between preclinical research and patient care.
• Further refinement of animal models is essential for developing novel immunomodulatory therapies for autoimmune liver diseases.